Seeking volunteers for working group on Inclusion, Diversity, Equity, and Accessibility (IDEA)


Inclusion, diversity, equity, and accessibility (IDEA) are at the centre of everything we do at Can-SOLVE CKD. These principles, which go hand in hand with patient-oriented research, represent one of the four pillars of Can-SOLVE CKD Phase 2.

At this time, we are forming a working group to assess the state of our IDEA actions and advise on how to enhance our commitment to these principles. We are seeking patient partners, researchers, administrators, and policy-makers interested in this area. Volunteers will come together to advise on a tool to capture the current state of the network’s IDEA practices, analyze the results, and co-develop a plan to address any gaps. The group will also co-write a process paper to share and mobilize the outcomes of its work.

Volunteer roles will be primarily advisory, but members may take on actual work as they are interested and able. We anticipate hiring a graduate student to be a hands-on resource for the work. The group will determine the timing and frequency of meetings. Patient partners will receive honoraria for their participation. We would like to start this work in February and expect it to last six to eight months.

Please contact if you are interested in volunteering.

Type of Participation

Patient Partnership


All provinces and territories

Related studies

  • Take part in one hemodialysis session to evaluate Qidni Labs’ nearly waterless and portable dialysis system

    Overview: Qidni Labs is inviting up to 30 patients with kidney failure to take part in research studying the “Qidni/D”, an investigational hemodialysis device, as a possible treatment for kidney failure.

    Study type: Clinical Trial

    May 16, 2023

  • Person-centered integrated care delivery for patients with chronic kidney disease and multimorbidity in the primary care setting and primary-nephrology care interface

    Overview: Participants are invited to complete a 15-minute survey with questions about their experience with kidney care in Alberta.

    Study type: Survey

    May 16, 2023

  • Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE)

    Overview: The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.

    Study type: Clinical Trial

    April 28, 2023